Current and future therapy in haemochromatosis and Wilson’s disease

Bibliography

• MERRYWEATHER-CLARKE AT, POINTON JJ, SHEARMAN JD, ROBSON KJ: Global prevalence of putative hematochromatosis mutations.Med. Genet. (1997) 34:275–278.
   PubMed Web of Science ®Google Scholar
• LUCOTTE G: Celtic origin of the C282Y mutation of hematochromatosis. Blood Cells Dis. (1998) 24:433–438.
   PubMedGoogle Scholar
• FEDER JN, GNIRKE A, THOMAS Wet al.: A novel MHC class 1-like gene is mutated in patients with hereditary hematochromatosis. Nat. Genet. (1996) 13:399–408.
   Google Scholar
• BEUTLER E, FELITTI VJ, KOZIOL JA, HO NJ, GELBART T: Penetrance of 845G- A (C282Y)HFE hereditary hemochromatosis mutation in the USA. Lancet (2002) 359:211–218.
   PubMed Web of Science ®Google Scholar
• GOCHEE PA, POWELL LW, CULLEN DJ, DU SART D, ROSSI E, OLYNYK JK: A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology (2002) 122(3):646–651. Erratum in: Gastroenterology (2002) 122(4):1191.
   Google Scholar
• ROETTO A, TOTARO A, CAZZOLLA M et al: Juvenile hematochromatosis locus mapsto chromosome lq. Am. j Hum. Genet. (1999) 64:1398–1393.
   Google Scholar
• WHITTINGTON CA, KOWDLEY KV: Review article: haemochromatosis.Aliment. Pharmocol. Ther. (2002) 16:19758.
   Google Scholar
• ADAMS PC, DEUGNIER Y,MOIRAND R, BRISSOT P: The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis.Hepatology (1997) 25:162–166.
   PubMed Web of Science ®Google Scholar
• ANDREWS NC: Disorders of iron metabolism. N Engl. Med. (1999) 341:1986–1995.
   PubMed Web of Science ®Google Scholar
• MCKIE AT, BARROW D,LATUNDE-DADA GO et al.: An iron-regulated ferric reductase associated with the absorption of dietary iron. Science (2001) 291:1755–1759.
   Google Scholar
• GUNSHIN H, MACKENZIE B, BERGER UV et al.: Cloning and characterization of a mammalian proton-coupled metal-ion transported. Nature (1997) 388:482–488.
   PubMed Web of Science ®Google Scholar
• MCKIE AT, MARCIANI P, ROLES A et al.: A novel duodenal iron-regulated transporter, IREG 1, implicated in the basolateral transfer of iron to the circulation. Molec. Cell (2000) 5:299–309.
   PubMed Web of Science ®Google Scholar
• ABBOUD S, HAILE DJ: A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J. Biol. Chem. (2000) 275:19906–19912.
   PubMed Web of Science ®Google Scholar
• VULPE CD, KUO YM, MURPHY TL et al.: Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet. (1999) 21:195–199.
   PubMed Web of Science ®Google Scholar
• GARRICK MD, NUNEZ MT,OLIVARES M, HARRIS ED: Parallels and contrasts between iron and coppermetabolism. Biometals (2003) 16:1–8.
   PubMed Web of Science ®Google Scholar
• FINCH C: Regulators of iron balance in humans. Blood (1994) 84:1697–1702.
   PubMed Web of Science ®Google Scholar
• ROY CN, ENNS CA: Iron homeostasis: new tales from the crypt. Blood (2000) 96:4020–4027.
   PubMed Web of Science ®Google Scholar
• PARKKILA S, WAHEED A, BRITTON RSet al.: Immnohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc. Nati Acad. Sri. USA (1997) 94:2534–2539.
   Google Scholar
• WAHEED A, PARKKILA S, SAARNIO J et al.: Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum. Proc. Natl Acad. Sri. USA (1999) 96:1579–1584.
   PubMed Web of Science ®Google Scholar
• ROY CN, PENNY DM, FEDER JN,ENNS CA: The hereditaryhemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells. J. Biol. Chem. (1999) 274:9022–9028.
   PubMedGoogle Scholar
• BENNETT MJ, LEBRON JA, BJORKMAN PJ: Crystal structure of the hereditary hemochromatosis protein HFE complexed with transferrin receptor.Nature (2000) 403:45–53.
   Google Scholar
• FLEMING RE, MIGAS MC, ZHOU X et al.: Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transported DMT1. Proc. Nati Acad. Sci. USA (1999) 96:3143–3148.
   PubMed Web of Science ®Google Scholar
• ZOLLER H, PIETRANGELO A, VOGEL W, WEISS G: Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transported DMT1. Lancet (1999) 353:2120–2123.
   PubMed Web of Science ®Google Scholar
• ANDERSON GJ: The control of iron absorption. J. Castroenterol. Hepatol. (1996) 11:1030–1032.
   PubMedGoogle Scholar
• OLYNYK JK, CULLEN DJ, AQUILLA S, ROSSI E, SUMMERVILLE L,POWELL LW: A population based study of the clinical expression of the hemochromatosis gene. N Engl. I Med.v (1999) 341:718–724.
   PubMed Web of Science ®Google Scholar
• ADAMS PC, KERTESZ AE, VALBERG LS: Clinical presentation of hemochromatosis: A changing scene. Am." Med. (1991) 90:445–449.
   PubMed Web of Science ®Google Scholar
• MCDONNELL SM, PRESTON BL, JEWELL SA et al.: A survey of 2851 patients with hemochromatosis: Symptoms and response to treatment. Am. J. Med.(1999) 106:619–624.
   PubMed Web of Science ®Google Scholar
• BACON BR, SADIQ SA: Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am. J. Gast. (1997) 92:784–789.
   PubMed Web of Science ®Google Scholar
• TAVILL AS: Diagnosis and management ofhemochromatosis. Hepatology (2001) 33:1321–1328.
   PubMed Web of Science ®Google Scholar
• BASSETT ML, HALLIDAY JW, FERRIS RA, POWELL LW: Diagnosis of hemochromatosis in young subjects: Predictive accuracy of biochemical screening tests. Gastroenterology (1984) 87:628–633.
   PubMed Web of Science ®Google Scholar
• MCCLAREN CE, BARTON JC, ADAMS PC et al.: Hemochromatosis and iron overload study research investigators.Hemochromatosis and iron overload screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am. J. Med. Sci. (2003) 325:53–62.
   Google Scholar
• FARGION S, FRACANZANI AL, PIPERNO A et al.: Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology (1994) 20:1426–1431.
   PubMed Web of Science ®Google Scholar
• YAOUANQ JM: Diabetes and hemochromatosis: current concepts, management and prevention.Diabetes Metab. (1995) 21:319–329.
   Google Scholar
• KELLY TM, EDWARDS CQ, MEIKLE AW, KUSHNER JP:Hypogonadism in hemochromatosis: reversal with iron depletion. Ann. Intern. Med. (1984) 101:629–632.
   PubMedGoogle Scholar
• RIVERS J, GARRAHY P, ROBINSON W, MURPHY A: Reversible cardiac dysfunction in hemochromatosis.Am. Heart J. (1987) 113:216–217.
   PubMed Web of Science ®Google Scholar
• INES LS, DA SILAVAJA, MALCATA AB, PORTO AL: Arthropathy of genetic hemochromatosis: a major and distinctive manifestation of the disease. Clin. Exp. Rheum. (2001) 19:98–102.
   PubMedGoogle Scholar
• VAN ASBECK BS, VERBRUGH HA, VAN OOST VA, MARX JJ, IMHOF HW, VERHOEF J: Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. Br. Med." (1982) 284:542–544.
   PubMed Web of Science ®Google Scholar
• CARNIEL E, MAZIGH D,MOLLARET HH: Expression of iron-regulated proteins in Yersinia species and their relation to virulence. Infect. Immun. (1987) 55:277–280.
   PubMedGoogle Scholar
• BULLEN JJ, SPALDING PB, WARD CG, GUTTERIDGE JM: Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch. Intern. Med. (1991) 151:1606–1609.
   PubMed Web of Science ®Google Scholar
• SUGAR AM: Mucormycosis. Clin. Infect.Dis. (1992) 14\(Suppl. 1):5126–5129.
   Google Scholar
• KEBERLE H: The biochemistry of desferrioxamine and its relation to iron metabolism. Ann. NY Acad. Sci. (1964) 119:758–765.
   PubMed Web of Science ®Google Scholar
• ROTHMAN RJ, SERRONI A,FARBER JL: Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidase cell injury. Mol. Pharmacol. (1992) 42:703–710.
   PubMed Web of Science ®Google Scholar
• PORTER JB, ABEYSINGHE RD, MARSHALL L, HIDER RC, SINGH S:Kinetics of removal and reappearance pf non-transferrin-bound plasma iron with deferoxamine therapy. Blood (1996) 88:705–713.
   PubMed Web of Science ®Google Scholar
• SUMMERS ME JACOBS A, IUD WAY D, PERERA P, RICKETTS C: Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br..! Haematol. (1979) 42:547–555.
   PubMedGoogle Scholar
• DAVIS BA, PORTER JB: Long-term outcome of continuous 24-hour deferoxamine infusion via inswelling intravenous catheters in high-risk beta-thalassemia. Blood (2000) 95:1229–1236.
   PubMed Web of Science ®Google Scholar
• OLIVIERI NE BRITTENHAM GM: Iron-chelating therapy and the treatment of thalassemia. Blood (1997) 89:739–761.
   PubMedGoogle Scholar
• BRITTENHAM GM, GRIFFITH PM, NIENHUIS AW et al.: Efficacy of Deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl. I Med. (1994) 331:567–573.
   PubMed Web of Science ®Google Scholar
• OLIVIERI NE BUNCIC RJ, CHEW E et al.: Visual and auditory neurotoxicity in patients receiving subcutaneious Deferoxamine infusions. N Engl. .1. Med. (1986) 314:869–873.
   Google Scholar
• PIGA A, LUZZATTO L, CAPALBO P, GAMBOTTO S, TRICTA EGABUTTI V: High dose desferrioxamine as a cause of growth failure in thalassaemic patients. Eur. Haematol. (1988) 40:380–381.
   PubMed Web of Science ®Google Scholar
• KOWDLEY KV, KAPLAN MM: Iron chelation therapy with oral deferiprone-toxicity or lack of efficacy? N Engl. J. Med. (1998) 339:468–469.
   Google Scholar
• FREEDMAN MH, GRISARU D, OLIVIERI NE MACLUSKY I, THORNER PS: Pulmonary syndrome in patients with thalassemia major receiving intravenous Deferoxamine infusions. Am. I Dis. Child. (1990) 144:565–569.
   PubMedGoogle Scholar
• PORTER JB, JASWON MS,HUEHNS ER, EAST CA, HAZELL JVV:Desferrioxamine ototoxicity: Evaluation ofrisk factos in thalassaemic patients and guidelines for safe dosage. Br. J. Haematol. (1989) 73:403–409.
   PubMed Web of Science ®Google Scholar
• DRAGSTEN PR, HALLAWAY PE, HANSON GJ, BERGER AE,BERNARD B, HEDLUND BE: First human studies with a high-molecular-weight iron chelator. I Lab. Clin. Med. (2000) 135:57–65.
   PubMed Web of Science ®Google Scholar
• BORGNA-PIGNATTI C, COHEN A: Evaluation of a new method of administration of the iron chelating agent deferoxamine. Pediam (1997) 130:86–88.
   Google Scholar
• ARAUJO A, KOSARYAN M,MACDOWELL A et al.: A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload. Br: J. HaematoL (1996) 93:835–837.
   Google Scholar
• BARMAN BALFOUR JA, FOSTER RH: Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs (1999) 58:553–578.
   PubMed Web of Science ®Google Scholar
• OLIVIERI NF, KOREN G, MATSUI D et al.: Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator deferiprone in thalassemia intermedia. Blood(1992) 79:2741–2748.
   PubMed Web of Science ®Google Scholar
• OLIVIERI NF, BRITTENHAM GM, MATSUI D et al: Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl. J. Med. (1995) 332:918–922.
   PubMed Web of Science ®Google Scholar
• OLIVIERI NF, BRITTENHAM GM, MCLAREN CE et al.: Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl. J. Med. (1998) 339:417–423.
   PubMed Web of Science ®Google Scholar
• HOFFBRAND AV, AL-REFAIE F, DAVIS B et al.: Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood (1998) 91:295–300.
   PubMed Web of Science ®Google Scholar
• GIARDINA PJ, GRADY RW: Chelation therapy in beta-thalassemia: an optimistic update. Semin Hema (2001) 38:360–366.
   PubMed Web of Science ®Google Scholar
• COHEN AR, GALANELLO R, PIGA A, DIPALMA A, VULLO C, TRICTA F: Safety profile of the oral iron chelator deferiprone: a multicenter study. Br. J. Haematol (2000) 108:305–312.
   PubMed Web of Science ®Google Scholar
• GOGTEY J, AGARWAL MB, RAJADHYAKSHA G, MUNOT S: Deferiprone: A review of Indian study over 10 years, Proceedings of the lab International Conference on Oral Chelators in the Treatment of Thalassemia and Other Diseases and Biomed Meeting, Limassol, Cyprus, March 22–26 (2000).
   Google Scholar
• TONDURY P, NIELSEN P, FISCHER R, HIRT A: Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassemia patients, 1989–2000, Proceedings of the Igh International Conference on Oral Chelators M theTreatment of Thalassemia and Other Diseases and Biomed Meeting, Limassol, Cyprus, March 22–26 (2000).
   Google Scholar
• LINK G, KONJIN AM, BREUER W, CABANTCHIK ZI, HERSHKO C: Exploring the 'iron shuttle' hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J. Lab. Clin. Med. (2001) 138:130–138.
   PubMed Web of Science ®Google Scholar
• WONKE B, WRIGHT C,HOFFBRAND AV: Combined therapy with deferiprone and desferrioxamine. Br. J. Haematol (1998) 103:361–364.
   PubMed Web of Science ®Google Scholar
• AYDINOK Y, NISLI G, KAVAKLI K, COKER C, KANTAR M, CETINGUL N: Sequential use of deferiprone and desferrioxamine in primary school children with thalassemia major in Turkey.Acta Hema (1999) 102:17–21.
   PubMed Web of Science ®Google Scholar
• HERSHKO C, KONJIN AM, NICK HP, BREUER W, CABANTCHIK ZI, LINK G: ICL670A: a new synthetic oral chelator; evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood (2001) 97:1115–1122.
   PubMed Web of Science ®Google Scholar
• BERGERON RJ, WIEGAND J, BRITTENHAM GM: HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood (2002) 99:3019–3026.
   PubMed Web of Science ®Google Scholar
• WILSON SAK: Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brant (1912) 34:295–509.
   Google Scholar
• BRAMWELL B: Familial cirrhosis of the liver: four cases of acute fatal cirrhosis of the liver in the same family, the patients being respectively nine, ten, fourteen and fourteen years of age; suggested relationship to Wilson's progressive degeneration of the lenticular nucleus. Edin. Med. J. (1916) 17:90–99.
   Google Scholar
• CUMINGS JN: The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration.Brain (1948) 71:410–415.
   PubMed Web of Science ®Google Scholar
• FRYDMAN M, BONNE-TAMIR B, FARRER LA, CONNEALLY PM, MAGAZANIK A, ASHBEL S, GOLDWITCH Z: Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus'. Proc. Natl. Acad. Sci. USA (1985):1819.
   PubMedGoogle Scholar
• TANZI RE, PETRUKHIN KE, CHERNOV I et al: The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat. Genet. (1993):344.
   PubMedGoogle Scholar
• BULL PC, THOMAS GR,ROMMENS JM, FORBES JR, COX DW: The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet. (1993):327.
   PubMedGoogle Scholar
• HUNG IH, SUZUKI M, YAMAGUCHI Y, YUAN DS, KLAUSNER RD, GITLIN JD: Biochemical characterization of the Wilson disease protein and functional expression in he yeast Saccharomyces cerevisiae. J. Biol. Chem. (1997):21461.
   PubMedGoogle Scholar
• SCHAEFER M, HOPKINS RG,FAILLA ML, GITLIN JD: Hepatocyte-specific localization and copper-dependent trafficking of the Wilson's disease protein in the liver. Am. J. PhysioL Gastrointest Liver PhysioL (1999) 276:G639–G646.
   Google Scholar
• MZHEUSKAYA TI: Biological functions of ceruloplasmin and their deficiency caused by mutation in genes regulating copper and iron metabolism. Bull. Exp. Biol. Med. (2000) 130:719–727.
   PubMedGoogle Scholar
• LOUDIANOS G, GITLIN JD: Wilson's disease. Semin. Liver Dis. (2000) 20:353-364.ao.COX DW, ROBERTS EA: Wilson disease.In: Gastrointestinal and liver disease. Vol. 2. Feldman M, Friedman LS, Sleisenger MH, (Eds), Saunders, Philadelphia, USA (2002):1269–1277.
   Google Scholar
• PFEIL SA, LYNN DJ: Wilson's disease copper unfettered. J. Clin. Gastroenterol (1999) 29:22–31.
   PubMedGoogle Scholar
• MARTIN DA COSTA C, BALDWIN D, PORTMANN B, LOLIN Y, MOWAT AP, MIELE-VERGANI G: Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology (1992):609.
   PubMedGoogle Scholar
• WALSHE JM, YEALLAND M: Chelation treatment of neurological Wilson's disease. Q. Med. (1993) 86:197–204.
   PubMedGoogle Scholar
• SCHILSKY M: Diagnosis and treatment of Wilson's disease. Pediam Transplant. (2002) 6:15–19.
   PubMed Web of Science ®Google Scholar
• BREWER GJ: Zinc acetate for the treatment of Wilson's disease. Expert Opin. Pharmacother. (2001) 2:1473–1477.
   PubMedGoogle Scholar
• WALSHE JM: Penicillamine, a new oral therapy for Wilson's disease. Am. J. Med. (1956) 21:487–495.
   PubMed Web of Science ®Google Scholar
• PHYSICIANS' DESK REFERENCE: Vol. 1. Montvale: Medical Economics Company, Inc., (2002):3635.
   Google Scholar
• MJOLNEROD OK, DOMMERUD SA, RASMUSSEN K, GJERULDSEN ST: Congential connective tissue defect probably due to D-penicillamine treatment in pregnancy. Lancet (1971) 1:673–675.
   PubMed Web of Science ®Google Scholar
• SOLOMON L, ABRAMS G, DINNER M,BERMAN L: Neonatal abnormalities associated with d-penicillamine treatment during pregnancy. N Engl. I Med. (1977) 296:54–55.
   PubMed Web of Science ®Google Scholar
• HSU H, HUANG F, NI Y, CHANG M: Steroids used to desensitize penicillamine allergy in Wilson disease. Acta Paediatr. (1999) 40:448–450.
   Google Scholar
• SVETEL M, STERNI N, PEJOVI S, KOSTI VS: Penicillamine-induced lethal status dystonicus in a patient with Wilson's disease. Mov. Disord. (2001) 16:568–569.
   PubMedGoogle Scholar
• HUANG CC, CHU NS: Wilson's disease: resolution of MRI lesions following long-term oral zinc therapy. Acta Neurol. Scand. (1996) 93:215–218.
   PubMed Web of Science ®Google Scholar
• BREWER GJ: Pencillamine should not be used as initial therapy in Wilson's disease. Mov. Disord. (1999) 14:551–554.
   PubMed Web of Science ®Google Scholar
• GIBBS KR, WALSHE LM: In: Orphan diseases and orphan drugs. Scheinberg IH, Walshe JM (Eds), Manchester University Press, London, UK (1986):33–42.
   Google Scholar
• KODAMA H, MURATA Y, IITSUKA T, ABE T: Metabolism of administered triethylene tetramine dihydrochloride in humans. Life Sci. (1997) 61:899–907.
   PubMed Web of Science ®Google Scholar
• WALSHE JM, COX DW: Effects of treatment of Wilson's disease on natural history of haemochromatosis. Lancet (1998) 352:112–113.
   PubMed Web of Science ®Google Scholar
• PERRY AR, PAGLIUCA A, FITZSIMONS EJ, MUFTI GJ, WILLIAMS R: Acquired sideroblastic anaemia induced by copper-chelating agent. Int. Hematol (1996) 64:69–72.
   PubMed Web of Science ®Google Scholar
• KEEN CL, LONNERDAL B,HURLEY LS: Teratogenic effect of copper deficiency and excess. In: Inflammatory diseases and Copper. Sorenson JRJ (Ed.), Humana Press, Clifton NJ, USA (1982):109–121.
   Google Scholar
• BREWER GJ, JOHNSON VD, DICK RD, FINK JK, KLUIN KJ, HEDERA P: Treatment of Wilson's disease with zinc XVII: Treatment during pregnancy. Hepatology (2000) 31:364–370.
   PubMed Web of Science ®Google Scholar
• SCHOUWINK G: De hepato-cerebrale degeneratie (met een onderzoek van de zinkstofwisseling). Arnhem, Van der Mel (1961).
   Google Scholar
• HOOGENRADD TU, VAN DEN HAMER CJA: Three years of continuous zinc therapy in four patients with Wilson's disease. Acta Neurol Scand. (1983) 67:356–264.
   PubMedGoogle Scholar
• BREWER GJ, DICK RD,JOHNSON VD, FINK JK, KLUIN KJ, DANIELS S: Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years. .1 Lab. Clin. Med. (2001) 137:191–198.
   Google Scholar
• FOOD AND DRUGADMINISTRATION: Teratologic evaluation of FDA 71-49 (zinc sulfate). Food and Drug Administration, United States Department of Commerce Publications PD-221 805 (1973).
   Google Scholar
• BREWER GJ, YUZBASIYAN-GURKAN V, JOHNSON V, DICK RD, WANG Y: Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents.Am. Col. Nutr. (1993) 12:26–30.
   PubMedGoogle Scholar
• ESMAELI B, BURNSFINE MA, MARTONYI CL, SUGAR A, JOHNSON V, BREWER GJ: Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease. Cornea (1996) 15:582-588.los. BREWER GJ, DICK RD,JOHNSON VD, BRUNBERG JA, KLUIN KJ, FINK JK: Treatment of Wilson's disease with zinc: XV long-term follow-up studies.' Lab. Clin. Med. (1998) 132:264–278.
   Google Scholar
• OGRA Y, KOMADA Y, SUZUKI KT: Comparative mechanism and toxicity of tetre- and dithiomolybdates in the removal of copper.' [Borg. Biochem. (1999):199–204.
   Google Scholar
• WALSHE JM: Tetrathiomolybdate (Mo54) as an 'anti-copper' agent in man. In: Orphan diseases and orphan drugs (Vol.])Scheinberg IH, Walshe JM (Eds), Manchester University Press, Manchester, UK (1986):68–75.los. BREWER GJ, JOHNSON V, DICK RD, KLUIN KJ, FINK JK, BRUNBERG JA: Treatment of Wilson disease with ammonium tetrathiomolybdate: II. initial therapy in 33 neurologically affected patients and follow-up with zinc therapy [original contribution]. Arch. Neurol (1996) 53:1017–1025.
   Google Scholar
• KARUNAJEEWA H, WALL A, METZ J, GRIGG A: Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease. Aust. N41. Med. (1998) 28:215–216.
   PubMedGoogle Scholar
• CUMINGS JN: The effect of BAL in hepato-lenticular degeneration.Brain (1951) 74:10–22.
   PubMed Web of Science ®Google Scholar
• DENNY BROWN D, PORTER H: The effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease). N Engl. Med. (1951) 245:917–925.
   PubMedGoogle Scholar
• MUCKTER H, LIEBL B, REICHL F, HUNDER G, WALTHER U, FICHTL B: Are we ready to replace dimercaprol (BAL) as an arsenic antidote? Hum. Exp. Toxicol (1997) 16:460–465.
   PubMed Web of Science ®Google Scholar
• MINGSHAN R, RENMIN Y: Clinical curative effects of dimercaptusuccinic acid on hepatolenticular degeneration and the impact of DMSA on biliary trace elements. Chin. Med. J. (Eng) (1997) 110:694–697.
   PubMedGoogle Scholar